Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

British Journal of Cancer

Volumn 109, Issue 6, 2013, Pages 1414-1419

  Ahn, H K ^a,b   Choi, J Y ^a   Kim, K M ^a   Kim, H ^a   Choi, S H ^a   Park, S H ^a   Park, J O ^a   Lim, H Y ^a   Kang, W K ^a   Lee, J ^a   Park, Y S ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Gachon University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PAZOPANIB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; MALE; METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PYRIMIDINES; STOMACH NEOPLASMS; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884591569     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.470     Document Type: Article

References (21)

1. Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH (2012) Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 30: 2963-2968.
2. Hamberg P, Verweij J, Sleijfer S (2010) (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist 15: 539-547.
3. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, Modlin IM (2008) Neuroendocrine tumor epidemiology: Contrasting Norway and North America. Cancer 113: 2655-2664.
4. Hemminki K, Li X (2001) Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer 92: 2204-2210.
5. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15: 4220-4227.
6. Jensen EH, Kvols L, McLoughlin JM, Lewis JM, Alvarado MD, Yeatman T, Malafa M, Shibata D (2007) Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol 14: 780-785.
7. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gonen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J (2010) Pathology reporting of neuroendocrine tumors: Application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 34: 300-313.
8. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24: 401-406.
9. Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, King AG (2009) Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 101: 1717-1723.
10. Lepage C, Rachet B, Coleman MP (2007) Survival from malignant digestive endocrine tumours in England and Wales: A population-based study. Gastroenterology 132: 899-904.
11. Lim T, Lee J, Kim JJ, Lee JK, Lee KT, Kim YH, Kim KW, Kim S, Sohn TS, Choi DW, Choi SH, Chun HK, Lee WY, Kim KM, Jang KT, Park YS (2011) Gastroenteropancreatic neuroendocrine tumors: Incidence and treatment outcome in a single institution in Korea. Asia Pac J Clin Oncol 7: 293-299.
12. Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97: 934-959.
13. Naraev BG, Strosberg JR, Halfdanarson TR (2012) Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology 83: 117-127.
14. Phan A, Yao JC, Fogelman DR et al. (2010) A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 28 (suppl): 15s(abstr 4001
15. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364: 501-513.
16. Terris B, Scoazec JY, Rubbia L, Bregeaud L, Pepper MS, Ruszniewski P, Belghiti J, Flejou J, Degott C (1998) Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32: 133-138.
17. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008a) One hundred years after carcinoid': Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 3063-3072.
18. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen St S, Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 28: 69-76.
19. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen St S, Peter J, Cherfi A, Oberg KE (2011a) Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 96: 3741-3749.
20. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA (2008b) Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26: 1316-1323.
21. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011b) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523.